Spanish Version of the KBILD Questionnaire
Translation Into Spanish of an Interstitial Lung Disease Quality of Life Questionnaire (KBILD)
The purpose of the present study is to advance in the knowledge of quality of life in patients with ILD by translating a ILD quality of life questionnaire.
There are no specific tools validated in Spanish to evaluate the quality of life in patients with ILD, although these measures are useful for an comprensive evaluation of these patients.
Patients with ILD have a significant impact on their health. If we improve our Knowledge of the different domains affected by the disease, and not only in the pathophysiological ones, we will be able to develop tools to improve their management.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Recruiting
- Hospital De La Santa Creu I Sant Pau
-
Contact:
- Claudia Erika Delgado Espinoza
- Email: CDelgadoE@santpau.cat
-
Principal Investigator:
- Diego Castillo, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria
- Subjects older than 18 years.
- Diagnosis of ILD, established according to the consensus documents of the ATS and ERS [1,2].
- Acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits.
Exclusion criteria
- Another chronic respiratory disease other than EPID.
- Psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Validation of a specific quality of life questionnaire for patients with ILD
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIBSP-KBI-2016-47
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
NCT07332117RecruitingIdiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary Fibrosis
-
NCT07466420RecruitingIdiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary Fibrosis | Fibrotic Interstitial Lungs Diseases
-
NCT07515066Not yet recruiting
-
NCT07178392Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
NCT07162870Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
NCT07580053Active, not recruitingIdiopathic Pulmonary Fibrosis (IPF) | Familial Pulmonary Fibrosis | Telomere Disease | Progressive Pulmonary Fibrosis | Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)
-
NCT07583589Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
NCT07344558RecruitingIdiopathic Pulmonary Fibrosis (IPF)
-
NCT07194382RecruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Quality of life questionnaire
-
NCT03931096CompletedQuality of Life Assessment of Children With Congenital Heart Disease Aged 5 to 7 Years (QoL-CHD-5-7)Congenital Heart Disease
-
NCT04670874RecruitingCutaneous Lymphoma
-
NCT04650178Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 Infection
-
NCT00791635Active, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar Carcinoma
-
NCT04500600Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection
-
NCT03057639Terminated
-
NCT02728804CompletedStage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer
-
NCT04186884CompletedCaregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care SettingsMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant Neoplasm
-
NCT01866969CompletedUnspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid Cancer
-
NCT01949740TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx